"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 5 | 4 | 9 |
| 2006 | 1 | 7 | 8 |
| 2007 | 2 | 4 | 6 |
| 2008 | 5 | 2 | 7 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 6 | 7 |
| 2012 | 4 | 6 | 10 |
| 2013 | 3 | 8 | 11 |
| 2014 | 2 | 6 | 8 |
| 2015 | 5 | 9 | 14 |
| 2016 | 1 | 10 | 11 |
| 2017 | 4 | 10 | 14 |
| 2018 | 7 | 9 | 16 |
| 2019 | 10 | 10 | 20 |
| 2020 | 4 | 9 | 13 |
| 2021 | 6 | 14 | 20 |
| 2022 | 3 | 12 | 15 |
| 2023 | 4 | 18 | 22 |
| 2024 | 9 | 9 | 18 |
| 2025 | 7 | 8 | 15 |
| 2026 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Shifting Paradigm: Utilization and Outcomes with Neoadjuvant Chemotherapy for cT4 and cN2 Colon Cancers. Ann Surg Oncol. 2026 May; 33(5):3849-3860.
-
Does neoadjuvant systemic therapy in clinical T1-2 N0 human epidermal growth factor receptor 2-positive breast cancer increase the extent of axillary surgery? Surgery. 2026 Mar; 191:109907.
-
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. Eur Urol Focus. 2026 Jan; 12(1):16-18.
-
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncol. 2025 Nov; 21(26):3377-3384.
-
The role of preoperative chemotherapy in pediatric neuro-oncology: a single-center experience and a systematic review of the literature. J Neurosurg Pediatr. 2025 Jul 01; 36(1):75-88.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 11; 8:e2400287.
-
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 11 11; 42(11):1898-1918.e12.
-
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial. Gynecol Oncol. 2024 06; 185:143-147.
-
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024 Jan; 203(2):317-328.
-
Baseline and Post-NACT Imaging in Retinoblastoma With Optic Nerve Involvement: Can MRI Predict Prognosis? J Pediatr Ophthalmol Strabismus. 2024 Mar-Apr; 61(2):98-105.